We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smart Nanoparticles Deliver Selective Heating to Kill Tumors

By LabMedica International staff writers
Posted on 28 Jul 2016
Print article
Image: A team of scientists has discovered an organic ‘smart’ biodegradable nanoparticle, named PEARL, that uses light and heat in a controlled manner to target and destroy tumors with bigger precision (Photo courtesy of the University Health Network).
Image: A team of scientists has discovered an organic ‘smart’ biodegradable nanoparticle, named PEARL, that uses light and heat in a controlled manner to target and destroy tumors with bigger precision (Photo courtesy of the University Health Network).
Cancer researchers have demonstrated a novel type of "smart" nanoparticle that can destroy a tumor through selective heating while causing minimal damage to surrounding normal tissues.

Investigators at University Health Network (Toronto, Canada) described the use of PEARLs (photo-thermal enhancing auto-regulating liposomes) in a proof-of-concept paper that was published in the July 14, 2016, online edition of the journal Angewandte Chemie.

Photothermal therapy (PTT) is enhanced by the use of nanoparticles with a large optical absorption at the treatment wavelength. However, this comes at the cost of higher light attenuation that results in reduced depth of heating as well as larger thermal gradients, leading to potential over- and under-treatment in the target tissue. These limitations can be overcome by using PEARLs, which are based on thermochromic J-aggregate forming dye–lipid conjugates that reversibly alter their absorption above a predefined lipid phase-transition temperature.

The investigators showed - in nanoparticle solutions and in gel phantoms containing the nanoparticles - that under irradiation by near-infrared light, deeper layers of the target tissue reverted to the intrinsic optical absorption, halting the temperature rise and enabling greater light penetration and heat generation at depth.

Senior author Dr. Gang Zheng, professor of medical biophysics at the University Health Network, said, "Our smart nanoparticle is super cool. It can absorb light, generate heat, and ablate the tumor. It is a thermal sensor and once it reaches the desired ablation temperature of 55 degrees Celsius, it becomes invisible allowing the light to move deeper into more areas of tumor and repeat the treatment process. The result is a promising new way to heat and ablate larger volumes of tumor with minimal damage to surrounding tissues in a controlled and precise way. The next step is to conduct pre-clinical studies to test the concept further."

Related Links:
University Health Network


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.